Search Results - "Nicolini, Valeria G"

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines by Klein, Christian, Waldhauer, Inja, Nicolini, Valeria G., Freimoser-Grundschober, Anne, Nayak, Tapan, Vugts, Danielle J., Dunn, Claire, Bolijn, Marije, Benz, Jörg, Stihle, Martine, Lang, Sabine, Roemmele, Michaele, Hofer, Thomas, van Puijenbroek, Erwin, Wittig, David, Moser, Samuel, Ast, Oliver, Brünker, Peter, Gorr, Ingo H., Neumann, Sebastian, de Vera Mudry, Maria Cristina, Hinton, Heather, Crameri, Flavio, Saro, Jose, Evers, Stefan, Gerdes, Christian, Bacac, Marina, van Dongen, Guus, Moessner, Ekkehard, Umaña, Pablo

“…We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety…”
Get full text

The PET-tracer 89Zr-Df-IAB22M2C enables monitoring of intratumoral CD8 T cell infiltrates in tumor-bearing humanized mice after T cell bispecific antibody treatment by Griessinger, Christoph M, Olafsen, Tove, Mascioni, Alessandro, Jiang, Ziyue Karen, Zamilpa, Charles, Jia, Fang, Torgov, Michael, Romero, Jason M, Marchioni, Filippo, Satpayev, Daulet, Lee, Chenyu, Zhang, Green, Nayak, Tapan K, Pincha, Mudita, Amann, Maria, Mohan, Preethi Latha Bhavani, Richard, Marine, Nicolini, Valeria G, Sam, Johannes, Claus, Christina, Ferrara, Claudia, Brünker, Peter, Bacac, Marina, Umana, Pablo, Rüttinger, Dominik, Wilson, Ian A, Gudas, Jean, Klein, Christian, Tessier, Jean J L

“…CD8-expressing T cells are the main effector cells in cancer immunotherapy (CIT). Treatment-induced changes in intratumoral CD8+ T cells may represent a…”
Get full text

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy by Sam, Johannes, Hofer, Thomas, Kuettel, Christine, Claus, Christina, Thom, Jenny, Herter, Sylvia, Georges, Guy, Korfi, Koorosh, Lechmann, Martin, Eigenmann, Miro Julian, Marbach, Daniel, Jamois, Candice, Lechner, Katharina, Krishnan, Sreenath M., Gaillard, Brenda, Marinho, Joana, Kronenberg, Sven, Kunz, Leo, Wilson, Sabine, Briner, Stefanie, Gebhardt, Samuel, Varol, Ahmet, Appelt, Birte, Nicolini, Valeria, Speziale, Dario, Bez, Miriam, Bommer, Esther, Eckmann, Jan, Hage, Carina, Limani, Florian, Jenni, Silvia, Schoenle, Anne, Le Clech, Marine, Vallier, Jean-Baptiste Pierre, Colombetti, Sara, Bacac, Marina, Gasser, Stephan, Klein, Christian, Umaña, Pablo

“…•CD19-CD28 provides effective CD28 costimulation to glofitamab-activated T cells without superagonistic properties.•Triple combination with CD19–4-1BBL further…”
Get full text

Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents by Nicolini, Valeria G., Waldhauer, Inja, Freimoser-Grundschober, Anne, Richard, Marine, Fahrni, Linda, Bommer, Esther, Claus, Christina, Sam, Johannes, Colombetti, Sara, Sutmuller, Roger, Levesque, Mitchell P., Irmisch, Anja, Bleul, Conrad, Campbell, Neil, Bacac, Marina, Moessner, Ekkehard, Klein, Christian, Umana, Pablo

“…In the past decade, many checkpoint inhibitors (CPI) have been approved for melanoma, demonstrating the increasing potential of immunotherapy as a lifesaving…”
Get full text

Abstract 1129: Monitoring intratumoral CD8 T cell infiltrates in human stem cell engrafted mice during single agent and combination immunotherapy with T cell bispecific antibodies using the human PET-tracer 89Zr-Df-IAB22M2C by Griessinger, Christoph M., Mascioni, Alessandro, Jia, Fang, Torgov, Michael, Nayak, Tapan, Mohan, Preethi Latha Bhavani, Nicolini, Valeria G., Sam, Johannes, Claus, Christina, Ferrara-Koller, Claudia, Bacac, Marina, Umana, Pablo, Wilson, Ian, Klein, Christian, Tessier, Jean J.

“…A persisting challenge in cancer immunotherapies (CIT) is the determination of patients responding early during therapy. As major effector cells, CD8 cytotoxic…”
Get full text